Drug Database
Back to search

Netherlands· NL-676ed4a5e4b9

Tecartus 0.4-2.0 x 10^8 cellen, dispersie voor infusie

A brexucabtagene autoleucel product containing brexucabtageen autoleucel, registered in Netherlands by Kite Pharma EU B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC L01XL06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTecartus 0.4-2.0 x 10^8 cellen, dispe…ATCL01XL06REGISTER NO.NL-676ed4a5e4b9PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about brexucabtageen autoleucelAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Brexucabtagene autoleucel is registered in 13 of 19 countries.

Countries holding a registration under ATC L01XL06 (brexucabtagene autoleucel), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search brexucabtagene autoleucel products by name

Brexucabtagene autoleucel · ATC L01XL06

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
BREXUCABTAGEEN AUTOLEUCEL
Manufacturer
Kite Pharma EU B.V.
Country
Netherlands (NL)
ATC code
L01XL06
ATC class
Brexucabtagene autoleucel
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/20/1492

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

82 interactions on record for brexucabtagene autoleucel.

Graded by severity as the source publishes them — 51 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check brexucabtagene autoleucel against other medicinesHow interaction checks work

Brexucabtagene autoleucel · interactions on record

82 records

  • 51 severe
  • 31 moderate

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Brexucabtagene autoleucel in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All brexucabtagene autoleucel products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tecartus
  • Liechtenstein · Tecartus
  • Norway · Tecartus

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7960dd0a-0ca1-43be-9aac-2df8874159d9
GET /v1/drugs/7960dd0a-0ca1-43be-9aac-2df8874159d9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tecartus-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Brexucabtagene Autoleucel",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126203",
  "excipients": [
    "ADENOSINE",
    "CALCIUMCHLORIDE 2-WATER (E 509)",
    "DEXTRAAN 40",
    "DIMETHYLSULFOXIDE",
    "GLUCOSE 0-WATER",
    "GLUTATHION (L-)",
    "HUMAAN ALBUMINE",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
    "KALIUMHYDROXIDE (E 525)",
    "KALIUMWATERSTOFCARBONAAT (E 501 (II))",
    "LACTOBIONZUUR",
    "MAGNESIUMCHLORIDE 6-WATER (E 511)",
    "MANNITOL (D-) (E 421)",
    "N-2-HYDROXYETHYLPIPERAZINE-N'-2-ETHAANSULFONZUUR",
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "BREXUCABTAGEEN AUTOLEUCEL"
  ],
  "leaflet_url": null,
  "authorised_at": "2020/12/14",
  "procedure_number": "EMEA/H/C/005102",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/20/1492",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about brexucabtagene autoleucel.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console